Detalles de la búsqueda
1.
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Nature;
608(7923): 609-617, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35948633
2.
Augmented interpretation of HER2, ER, and PR in breast cancer by artificial intelligence analyzer: enhancing interobserver agreement through a reader study of 201 cases.
Breast Cancer Res;
26(1): 31, 2024 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38395930
3.
Tandem C/N-Difunctionalization of Nitroarenes: Reductive Amination and Annulation by a Ring Expansion/Contraction Sequence.
J Am Chem Soc;
145(1): 41-46, 2023 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36562776
4.
Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Oncologist;
28(2): e82-e91, 2023 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36082904
5.
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Nature;
609(7929): E13, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050473
6.
Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.
Oncologist;
26(1): e78-e89, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32885893
7.
Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics.
Oncologist;
26(4): e715-e718, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33522043
8.
Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
Oncologist;
26(1): e153-e163, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32918774
9.
Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.
Future Oncol;
17(31): 4101-4114, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463133
10.
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
Oncologist;
25(1): e147-e159, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31578273
11.
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.
Oncologist;
25(1): e39-e47, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31604903
12.
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Gastroenterology;
156(8): 2242-2253.e4, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30836094
13.
Recurrent secondary genomic alterations in desmoplastic small round cell tumors.
BMC Med Genet;
21(1): 101, 2020 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32393201
14.
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA.
Oncology;
98(12): 905-912, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32966992
15.
Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
Gynecol Oncol;
157(2): 357-366, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32156473
16.
Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
BJU Int;
125(5): 739-746, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31985116
17.
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Cancer;
125(7): 1185-1199, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30582752
18.
Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.
Oncologist;
24(4): e142-e145, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30659078
19.
Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Oncologist;
24(12): 1526-1533, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31292271
20.
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Oncologist;
24(5): 657-663, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30683711